Relapsing-Remitting Multiple Sclerosis


Multiple sclerosis is now a treatable disease and several immunomodulating therapies exist, but their clinical efficacy is moderate and treatment failure during the course of the disease is an increasing problem. As agents with different targets are available, the question was raised whether combination of these therapies would: (i) be safe; (ii) result in… (More)
DOI: 10.2165/00063030-200013030-00001

4 Figures and Tables


  • Presentations referencing similar topics